Somatopause, weaknesses of the therapeutic approaches and the cautious optimism based on experimental ageing studies...

Area of Science:

• Endocrinology
• Gerontology
• Nutritional Science

Background:

• Somatopause, linked to decreased growth hormone (GH) and insulin-like growth factor 1 (IGF-1), causes musculoskeletal, metabolic, and mental issues in aging individuals.
• Current treatments for somatopause, including GH therapy, present safety and efficacy concerns.
• Soy isoflavones are phytochemicals with demonstrated health benefits, prompting investigation into their potential for somatopausal symptom management.

Purpose of the Study:

• To investigate the potential of soy isoflavones, specifically genistein and daidzein, in ameliorating somatopausal symptoms.
• To evaluate the effects of soy isoflavones on the somatotropic system and related metabolic markers.

Main Methods:

• Experiments involved rat anterior pituitary cells, a rat model of mild andropause, ovariectomized ewes, and rams.
• Assessed genistein's effect on cAMP accumulation, GH release, and somatotropic system function.
• Evaluated daidzein's impact on body mass, bone mass, bone turnover, and cholesterol levels in an animal model of severe andropause.

Main Results:

• Genistein stimulated GH release and somatotropic system function in various animal models.
• Daidzein increased body and bone mass, reduced bone turnover, and lowered cholesterol in a severe andropause model.
• Both isoflavones demonstrated cholesterol-lowering effects.

Conclusions:

• Soy isoflavones, genistein and daidzein, show promise in addressing key aspects of somatopause.
• These findings suggest a potential therapeutic avenue for somatopausal symptoms, warranting further preclinical and clinical validation.
• Development of balanced soy isoflavone-based therapeutics is suggested for future research.